Testing effectiveness (Phase 2)WithdrawnNCT01859182
What this trial is testing
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
Who this might be right for
Adenocarcinoma of the GallbladderAdenocarcinoma With Squamous Metaplasia of the GallbladderAdult Primary Cholangiocellular Carcinoma+12 more
National Cancer Institute (NCI)